Emergent BioSolutions and Swiss biotech Rocketvax have announced that Emergent will make a strategic investment in Rocketvax parent company Swiss Rockets and will take over manufacturing and commercialization activities for 4 of Rocketvax’s intranasal vaccine candidates. Rocketvax’s pipeline includes live attenuated intranasal vaccines for melanoma and multiple sclerosis in addition to vaccines against viral diseases, including a nasal vaccine against SARS-CoV-2 that has been selected for Project NextGen.
Emergent President and CEO Joe Papa commented, “We are excited to partner with Rocketvax to accelerate the development of innovative products that address significant public health challenges. As Rocketvax is poised to progress its pipeline, we will stand ready to leverage our unique capabilities to ultimately bring these solutions to patients and communities in need. These four projects directly support Emergent’s strategic focus on growth and turnaround as part of our multi-year transformation plan.”
Rocketvax XEO Vladimir Cmiljanovic said, “This collaboration is a game changer for Rocketvax and the broader biotech industry. By partnering with Emergent BioSolutions, we are combining cutting edge vaccine innovation with world class production and regulatory expertise. This joint venture not only accelerates the development of next generation vaccines but also paves the way for groundbreaking advancements in global healthcare. Our shared vision is to revolutionize disease prevention and immunotherapy, bringing life saving solutions to millions worldwide. This collaboration is a major milestone for Rocketvax. By joining forces with Emergent, we can leverage their world class production capabilities to deliver next generation vaccines that have the potential to transform disease prevention and immunotherapy.”
Read the Emergent BioSolutions and Rocketvax press release
